Alnylam Pharmaceuticals Inc
LSE:0HD2
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Alnylam Pharmaceuticals Inc
LSE:0HD2
|
US |
|
M
|
Microsoft Corp
XHAM:MSF
|
US |
|
E
|
EMCOR Group Inc
SWB:EM4
|
US |
|
M
|
Medline Inc
NASDAQ:MDLN
|
US |
|
C
|
Credicorp Ltd
BMV:BAPN
|
PE |
|
InterContinental Hotels Group PLC
F:IC1B
|
UK |
|
A
|
Asics Corp
OTC:ASCCY
|
JP |
|
I
|
Interpublic Group of Companies Inc
SWB:IPG
|
US |
|
Vibra Energia SA
OTC:PETRY
|
BR |
|
N
|
Nikon Corp
XHAM:NKN
|
JP |
|
TTM Technologies Inc
F:TT1
|
US |
|
T
|
Trimble Inc
XBER:TB5
|
US |
|
Bukalapak.com Tbk PT
F:5E9
|
ID |
|
A
|
Advantest Corp
SWB:VAN
|
JP |
|
N
|
National Grid PLC
XHAM:NNGF
|
UK |
|
K
|
Kao Corp
XMUN:KAO
|
JP |
Bankruptcy Probability
Alnylam Pharmaceuticals Inc's probability of bankruptcy is Hidden . The solvency score is Hidden .
We take all the information about a company's solvency, such as how easily it can pay interest on outstanding debt, how much cash it has, the amount of debt, and more, and use it to estimate the probability of bankruptcy.
Solvency Ratios
Solvency Ratios Comparison
Alnylam Pharmaceuticals Inc Competitors
| Country | Company | Market Cap | D/E | D/A |
Interest Coverage |
Altman Z-Score |
Quick Ratio |
Current Ratio |
Cash Ratio |
||
|---|---|---|---|---|---|---|---|---|---|---|---|
| US |
|
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
39.4B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
356.3B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
179.1B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
163B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
109.3B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
75.6B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
41.5B EUR |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
57.8B AUD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Alnylam Pharmaceuticals Inc's probability of bankruptcy is Hidden .
The probability of bankruptcy is estimated using credit risk models that assess financial health, debt levels, interest coverage, and other solvency indicators.
As of the latest report, Alnylam Pharmaceuticals Inc has total debt of 2.5B USD. This includes both short-term (0 USD) and long-term (2.5B USD) debt.
You can find a full breakdown on its Balance Sheet.
